Arrowhead Pharmaceuticals (ARWR) saw its stock price surge 8.61% during intraday trading on Monday, driven by the U.S. FDA's approval of its first siRNA therapy, REDEMPLO (plozasiran), for treating familial chylomicronemia syndrome (FCS).
The approval marks a pivotal milestone for Arrowhead, transitioning it into a commercial-stage company. REDEMPLO, a quarterly self-administered treatment, opens new revenue streams and validates the company's RNAi platform. Additionally, a global licensing agreement with Novartis, worth up to $2 billion, further strengthens Arrowhead's financial position and investor confidence.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments